Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis

Veterinary Parasitology
Sergi SegarraJose J Cerón

Abstract

First-line treatment for canine leishmaniosis (CanL) is N-methylglucamine antimoniate (MGA) combined with allopurinol. However, in some dogs allopurinol may induce hyperxanthinuria leading to urolithiasis. Moreover, allopurinol resistance has recently been described in Leishmania infantum isolates from treated dogs with a relapse of the disease. Alternative treatments are thus needed. Since the type of host immune response strongly influences CanL progression and prognosis, dogs could benefit from treatments targeted at modulating such response, such as nucleotides and active hexose correlated compound (AHCC). The aim of this study was to evaluate the effects of an oral combination of nucleotides and AHCC in dogs with clinical leishmaniosis. Sixty-nine dogs with naturally-occurring clinical leishmaniosis were included in this multicenter, open-label, positively-controlled clinical trial and randomized to receive 10mg/kg allopurinol PO BID (allopurinol group) or 17mg/kg AHCC plus 32mg/kg nucleotides PO SID (supplement group) for 180 days. All dogs were also given 50mg/kg MGA SC BID during the first 28 days. At the time points 0, 30, and 180 days of the trial, dogs underwent a clinical examination, and blood, urine, and bone marr...Continue Reading

Citations

Sep 2, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·María Auxiliadora Dea-AyuelaFrancisco Bolás-Fernández
Aug 2, 2019·Animals : an Open Access Journal From MDPI·Pietro LombardiLaura Cortese
Oct 28, 2020·The Journal of Small Animal Practice·X RouraA Zatelli
Nov 9, 2019·Research in Veterinary Science·A Muñoz-PrietoA Tvarijonaviciute
Jul 8, 2019·Research in Veterinary Science·Marta BaxariasLaia Solano-Gallego

❮ Previous
Next ❯